tbuckley/cabot-search huggingface dataset:
Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma
Authors: Vivek Narayan, Stephen Keefe, Naomi Haas, Le Wang, Igor Puzanov, Mary Putt, Anna Catino, James Fang, Neeraj Agarwal, David Hyman, Amanda M. Smith, Brian S. Finkelman, Hari K. Narayan, Steven Ewer, Chantal ElAmm, Daniel Lenihan, Bonnie Ky
Journal: Clinical Cancer Research (2017)

Abstract Purpose: To prospectively evaluate cardiotoxicity risk with sunitinib in metastatic renal cell carcinoma (mRCC) routine clinical practice using comprehensive echocardiography and biomarker phenotyping. Experimental Design: In a multicenter prospective study of 90 patients with mRCC, echocardiography and biomarkers of cardiovascular injury and stress were quantified at baseline, 3.5, 15, and 33 weeks following sunitinib initiation. These “on-drug” visits corresponded to cycles 1, 3, and 6, respectively. Left ventricular (LV) dysfunction was defined as an absolute decline in LV ejection fraction (LVEF) by ≥10% to a value of &amp;lt;50%. Conditional survival analyses predicted the risk of LV dysfunction. Linear mixed-effects models estimated changes in LVEF, high-sensitivity Troponin I (hsTnI), and B-type natriuretic peptide (BNP) over time. Results: The predicted risk of LV dysfunction by cycle 6 was 9.7% (95% confidence interval, 3%–17%). The majority of events occurred in the first treatment cycle. This risk diminished to 5% and 2% in patients who had not experienced dysfunction by the completion of cycles 1 and 3, respectively. All evaluable patients who experienced LV dysfunction had subsequent improvement in LVEF with careful management. Six patients (6.7%) developed hsTnI elevations &amp;gt;21.5 pg/mL, and 11 additional patients (12.2%) developed BNP elevations &amp;gt;100 pg/mL. These elevations similarly tended to occur early and resolved over time. Conclusions: On average, patients with mRCC receiving sunitinib exhibit modest declines in LVEF and nonsignificant changes in hsTnI and BNP. However, approximately 9.7% to 18.9% of patients develop more substantive abnormalities. These changes occur early and are largely recoverable with careful management. Clin Cancer Res; 23(14); 3601–9. ©2017 AACR.
Primary colon cancer site as a predictor of bevacizumab effectiveness in metastatic colon cancer patients.
Authors: R. Islam, P. Chyou, H. Ege, A. Deedon, J. K. Burmester
Journal: Journal of Clinical Oncology (2011)

574 Background: Bevacizumab has been approved by the FDA for first-line treatment in combination with chemotherapy for metastatic colon cancer. Although bevacizumab extends progression free survival and overall survival for many metastatic colon cancer patients, primary cancer site has not been examined as a predictor of its effectiveness. Methods: Data regarding bevacizumab treatment for colorectal cancer were abstracted from the medical record of 175 patients treated at a large multi-specialty clinic. Data were collected regarding demographics, body mass index, weight loss, lifestyle variables (smoking status, drinking habit), history of colon polyps, family history of cancer, primary site of tumor in the colon, tumor stage, lymph node involvement, metastasis, tumor grade of metastasis, cancer cell type, symptoms related to the cancer, and other comorbidities (cardiovascular disease, diabetes mellitus, Crohn's disease, diverticulitis, and irritable bowel syndrome).Tumor response was measured by radiologic and biochemical markers. Univariate and multivariate analyses were performed using Fisher's exact test, Wilconox rank sum test, and unconditional logistic regression modeling. Results: Univariate analysis demonstrated that positive tumor response was positively correlated with blood in stool (p=0.0301), advanced lymph node stage (p=0.048), and adenocarcinoma cancer cell type (p=0.0387), but negatively correlated with chemotherapy treatment of the primary tumor (p=0.0387) and primary site of the colon cancer (p=0.0328). Multivariate stepwise logistic regression analysis demonstrated that patients with primary tumor located in the transverse or descending/sigmoid colon were more likely (odds ratio=5.88, 95% confidence interval: 1.72–20.00; p=0.0046) to have a positive tumor response than patients whose primary tumor site was cecal/ascending colon. Conclusions: Primary site of metastatic colon cancer may influence the effectiveness of bevacizumab therapy. Future randomized, controlled trials are needed to examine the primary site as a predictor of tumor response in metastatic colon cancer patients using bevacizumab therapy. No significant financial relationships to disclose.
Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
Authors: Holbrook E Kohrt, Lu Tian, Li Li, Ash A. Alizadeh, Sue Hsieh, Samuel Strober, Minnie Sarwal, Robert Lowsky
Journal: Blood (2012)
Genetic Variations in Heparanase Gene (HPSE) Are Associated with Increased Risk of Graft Vs. Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Effect of Discrepancy Between Recipient and Donor.
Authors: Olga Ostrovsky, Avichai Shimoni, Israel Vlodavsky, Arnon Nagler
Journal: Blood (2009)
T2* MRI Provides No Evidence for Myocardial and Pancreatic Iron Overload in Multitransfused Patients with Sickle/β-Thalassemia.
Authors: Hussam Ghoti, Orly Goitein, Elie Konen, Ariel Koren, Carina Levin, Alan Berebi, Pinhas Stark, Eliezer Rachmilewitz
Journal: Blood (2008)
Long-term follow-up of a multicenter phase II study of chemo-immunotherapy in the treatment of metastatic colorectal cancer (MCC).
Authors: F. Recchia, G. Candeloro, S. Necozione, P. Lippe, G. Desideri, S. Rea
Journal: Journal of Clinical Oncology (2011)

536 Background: The combination of low-dose interleukin-2 (IL-2) and 13-cis retinoic acid (RA) has been shown to decrease vascular endothelial growth factor (VEGF) of patients with MCC (Anticancer Res, 2005). Moreover, results of various studies have shown that the addition of IL-2 and RA to chemotherapy (CT) increased treatment efficacy, inducing a statistically significant decrease of VEGF, with a low cost. Methods: Patients with MCC, deemed unresectable, were given the following treatment for two consecutive days (D1-D2): Oxaliplatin 50 mg/m 2 , Leucovorin (LV), 200 mg/m 2 , 5-fluorouracil (5-FU) 400 mg/m 2 , Capecitabine (C) 2,000 mg/m 2 (FOCFOX). After 2 weeks Camptothecin, 90 mg/m 2 (D1-D2), was administered with the same doses of LV, 5-FU and C (FOCFIRI) as first-line treatment of MCC. Subcutaneous IL-2 1.8 x 10 6 I.U. and oral RA, 0.5 mg/kg were given 5 days/week. Induction CT was administered for 12 courses, alternating FOCFOX and FOCFIRI, followed by maintenance treatment with the same schedule of IL-2 + RA, for 3 weeks/month. The primary endpoint was the decrease ≥ 30% of VEGF of patients with MCC. Secondary endpoints were the cost of IL-2 and RA with respect to bevacizumab, toxicity, progression- free survival (PFS), and overall survival (OS). Results: From 08/2000 to 08/2006, fifty-four patients with MCC were entered into the trial. After a median follow up of 64 months (95% CI 62-85%), a statistically significant &gt; 30% (p&lt;0.001) decrease of VEGF was observed. Costs of therapy were $ 304.00/month for IL-2/RA and $ 1,700.00/month for bevacizumab (82% cost reduction). The most common adverse events of CT were grade 3/4 neutropenia, leukopenia, thrombocythopenia, and anemia in 33%, 9%, 2%, and 2% of patients, respectively, peripheral neuropathy in 10% of patients. Mild cutaneous skin rash, fever and autoimmune reactions were observed in the patients who received the maintenance immunotherapy. PFS at 10 months was 76% (95% CI 62-86). Median PFS was 27.8 months, while median OS was 48.8 months. Conclusions: These data show that maintenance immunotherapy with low-dose IL-2 and oral RA in patients with MCC has a low toxicity profile, is cost effective, decrease VEGF and seems to improve expected PFS and OS. No significant financial relationships to disclose.
Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers
Authors: I. Vergote, B. Lund, H. Havsteen, Z. Ujmajuridze, E. Van Nieuwenhuysen, C. Haslund, T. Juhler-Nøttrup, P. Neven, M. Mau-Sørensen, P. Berteloot, A. Kranich, T. Rashal, J. Meade, Y. Landesman, J.-R. Saint-Martin, G. Wright, M. Crochiere, S. Shacham, M. Kauffman, M. Raza Mirza
Journal: Annals of Oncology (2016)
Submicroscopic Interstitial Deletions in 13q14 Are Detectable in Metaphase Cells by Fluorescence In Situ Hybridization (FISH) with D13S319 in Chronic Lymphocytic Leukemia (B-CLL).
Authors: Daniel L. Van Dyke, Kimberly Stockero, Stephanie Fink, Stephanie Smoley, Sarah Paternoster, Susan Schwager, Tait Shanafelt, Clive Zent, Timothy Call, Neil Kay, Gordon Dewald
Journal: Blood (2005)
Outcome Analysis of DLBCL in HIV-infected and non-HIV-infected patients
Authors: Yusuke Kanemasa, Tatsu Shimoyama, Yuki Sasaki, Miho Tamura, Takeshi Sawada, Yasushi Omuro, Ryoko Sekiya, Naoki Yanagisawa, Akifumi Imamura, Tsunekazu Hishima, Yoshiharu Maeda
Journal: Annals of Oncology (2016)
Association of baseline health-related quality of life and survival in esophagogastric cancers.
Authors: L. F. Onate-Ocana, P. Mireles-de-Villafranca, J. F. Carrillo, D. Vilar-Compte, G. García-Hubard, V. Aiello-Crocifoglio
Journal: Journal of Clinical Oncology (2011)

118 Background: Baseline health-related quality of life (HRQL) is a prognostic factor for survival in patients with cancer; however contradictory results have been reported. We studied whether HRQL scores are associated with survival in patients with esophagogastric cancers. Methods: Patients with biopsy proven esophagogastric cancer were recruited prospectively. All were invited to respond the EORTC QLQ-C30 questionnaire. The prognostic role of usual clinical variables and HRQL data was analyzed dividing patients in two groups: 1) palliative intention or 2) curative intention treatments. The Kaplan-Meier and Cox's methods were used for bivariate or multivariate analysis, respectively. Results: A total of 259 cases were included, 99 were woman and 160 male (mean age 54.3). One-hundred thirty-three patients of group one, presented significant association with survival in nine of 15 HRQL scales (p &lt; 0.05). A multivariate model was constructed including basal serum albumin (hazard ratio [HR] 0.48; 95% confidence intervals [CI]: 0.34–0.68), Role functioning scale (HR 0.989; 95% CI: 0.98–0.99), Social functioning scale (HR 1.01; 95% CI: 1.005–1.019) and Nausea/Vomiting scale (HR 1.01; 95% CI: 1.01; 95% CI 1.006–1.02) (model p &lt; 0.0001). One-hundred twenty-six patients of group two, presented significant association with survival in eight of 15 HRQL scales (p &lt; 0.05). A multivariate model was constructed including definitive TNM stages (HR 8.7, 14.2, 10.1 for stages II, III and IV, respectively; reference category stage I), age (HR 1.04; 95% CI: 1.009–1.065), Social functioning scale (HR 0.98; 95% CI: 0.98–0.99), Pain scale (HR 1.024; 95% CI: 1.01–1.04) (model p &lt; 0.0001). Conclusions: These results suggest that HRQL provide significant prognostic information in addition to traditional clinical measures in patients with esophagogastric cancer. Prospective confirmatory studies are warranted. No significant financial relationships to disclose.
Dectin-2 Deficiency Modulates Th1 Differentiation and Improves Wound Healing After Myocardial Infarction
Authors: Xiaoxiang Yan, Hang Zhang, Qin Fan, Jian Hu, Rong Tao, Qiujing Chen, Yoichiro Iwakura, Weifeng Shen, Lin Lu, Qi Zhang, Ruiyan Zhang
Journal: Circulation Research (2017)

Macrophages are involved in wound healing after myocardial infarction (MI). The role of Dectin-2, a pattern recognition receptor mainly expressed on myeloid cells, in the infarct healing remains unknown.The aim of this study is to determine whether Dectin-2 signaling is involved in the healing process and cardiac remodeling after MI and to elucidate the underlying molecular mechanisms.In a mouse model of permanent coronary ligation, Dectin-2, mainly expressed in macrophages, was shown to be increased in the early phase after MI. Dectin-2 knockout mice showed an improvement in the infarct healing and cardiac remodeling, compared with wild-type mice, which was demonstrated by significantly lower mortality because of cardiac rupture, increased wall thickness, and better cardiac function. Increased expression of α-smooth muscle actin and collagen I/III was observed, whereas the levels of matrix metalloproteinase-2 and matrix metalloproteinase-9 were decreased in the hearts of Dectin-2 knockout mice after MI. Dectin-2 deficiency inhibited the rate of apoptotic and necrotic cell death. However, Dectin-2 did not affect immune cell infiltration and macrophage polarization, but it led to a stronger activation of the Th1/interferon-γ immune reaction, through the enhancement of interleukin-12 production in the heart. Interferon-γ was shown to downregulate transforming growth factor-β-induced expression of α-smooth muscle actin and collagen I/III in isolated cardiac fibroblasts, leading to a decrease in migration and myofibroblast differentiation. Finally, Dectin-2 knockout improved myocardial ischemia-reperfusion injury and infarct healing.Dectin-2 leads to an increase in cardiac rupture, impairs wound healing, and aggravates cardiac remodeling after MI through the modulation of Th1 differentiation.
Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR +, HER2- metastatic breast cancer
Authors: S. Loibl, A. Demichele, N.M. Turner, M. Cristofanilli, S. Loi, S. Verma, H. Bhattacharyya, Z. Ke, C. Giorgetti, C.H. Bartlett, S. Iyer, M. Colleoni, N. Masuda, S.-A. Im, N. Harbeck
Journal: Annals of Oncology (2016)
Haemostasis Assessed by Rotational Thromboelastometry and Thrombin Generation Test in Behcet's Disease Patients,
Authors: Ihosvany Fernández Bello, Elena G. Arias Salgado, Francisco Javier López-Longo, Mayte Álvarez Román, Isabel Rivas, Mónica Martín Salces, Ana Gonzalez Vigo, Miguel Canales, Víctor Jiménez-Yuste, Nora V. Butta
Journal: Blood (2011)
A japanese survey on first attempts of percutaneous transluminal coronary angioplasty.
Authors: Morie Sekiguchi, Toshihiko Ban, Masao Chino, Masahiro Endo, Kiyoshi Fujimoto, Koichi Higa, Motokazu Hori, Hirofumi Kanbara, Kazuhisa Kodama, Masamichi Nakajima, Tadayuki Shimakura, Youichi Shimizu, Yoshimasa Yabe, Morihiro Yoshida
Journal: Circulation (1985)

Experiences of the initial application of percutaneous transluminal coronary angioplasty (PTCA) in Japan performed during 1980-1981 at the multicenter level were analyzed. A survey in 72 cases which were collected from 12 centers showed an overall success rate of 64.7%, unimproved stenotic lesions in 8.1% and unpassable lesions in 24.3% of the cases. Complications were death of the patient in 2(2.8%), acute myocardial infarction in 6(8.3%) and dissection of the coronary artery in 3 cases (4.2%). Aortocoronary bypass graft surgery was performed in 8 cases (11.1%).
Cooperating Effect of Rps14, Csnk1a1 and miRNA145/miRNA146a Haploinsufficiency in the Activation of the Innate Immune System in Del(5q) MDS
Authors: Schneider K. Rebekka, Monica Schenone, Monica Ferreira Ventura, Fabian Beier, Tim H. Bruemmendorf, Ulrich Germing, Uwe Platzbecker, Guntram Büsche, Marie E. McConkey, Christopher S Waters, R. Coleman Lindsley, Benjamin L. Ebert
Journal: Blood (2015)
Differential Protein Expression in MBL and CLL: LAIR1 Is a Powerful Surface Marker for Identifying Cases with Adverse Cellular Features.
Authors: Andy C Rawstron, Darren J Newton, Ruth M. de Tute, Jane Shingles, Fiona L Bennett, Paul A.S. Evans, Sheila J.M. O’Connor, Andrew S Jack, Peter Hillmen
Journal: Blood (2008)
Inhaler device handling: have we really started to address the problem?
Authors: Sinthia Z. Bosnic-Anticevich
Journal: European Respiratory Journal (2017)

How big a problem is inhaler technique and how important is it? In this issue of the European Respiratory Journal we are presented with a "real-life" study exploring the inhaler technique of almost 3000 patients with chronic obstructive pulmonary disease (COPD) and the relationship between inhaler device handling and disease control. This observational, cross-sectional study, conducted by Molimard et al. [1], assesses the handling of devices by patients visiting general practitioners and pulmonologists and in so doing determines two key findings. 1) Over 50% of patients with COPD are not able to use their devices correctly. 2) Patients making "critical errors" in their device handling are two-times more likely to experience severe COPD exacerbations than those not making critical errors (3.3% versus 6.9% in the previous 3 months, respectively, OR 1.86). Let's consider again: how big a problem is inhaler technique and how important is it? <http://ow.ly/rwfu308ircJ>
Endothelial LOX-1 activation differentially regulates arterial thrombus formation depending on oxLDL levels: role of the Oct-1/SIRT1 and ERK1/2 pathways
Authors: Alexander Akhmedov, Giovanni G. Camici, Martin F. Reiner, Nicole R. Bonetti, Sarah Costantino, Erik W. Holy, Remo D. Spescha, Simona Stivala, Ariane Schaub Clerigué, Thimoteus Speer, Alexander Breitenstein, Jasmin Manz, Christine Lohmann, Francesco Paneni, Juerg-Hans Beer, Thomas F. Lüscher
Journal: Cardiovascular Research (2017)

The lectin-like oxLDL receptor-1 (LOX-1) promotes endothelial uptake of oxidized low-density lipoprotein (oxLDL) and plays an important role in atherosclerosis and acute coronary syndromes (ACS). However, its role in arterial thrombus formation remains unknown. We investigated whether LOX-1 plays a role in arterial thrombus formation in vivo at different levels of oxLDL using endothelial-specific LOX-1 transgenic mice (LOX-1TG) and a photochemical injury thrombosis model of the carotid artery.In mice fed a normal chow diet, time to arterial occlusion was unexpectedly prolonged in LOX-1TG as compared to WT. In line with this, tissue factor (TF) expression and activity in carotid arteries of LOX-1TG mice were reduced by half. This effect was mediated by activation of octamer transcription factor 1 (Oct-1) leading to upregulation of the mammalian deacetylase silent information regulator-two 1 (SIRT1) via binding to its promoter and subsequent inhibition of NF-κB signaling. In contrast, intravenous injection of oxLDL as well as high cholesterol diet for 6 weeks led to a switch from the Oct-1/SIRT1 signal transduction pathway to the ERK1/2 pathway and in turn to an enhanced thrombotic response with shortened occlusion time.Thus, LOX-1 differentially regulates thrombus formation in vivo depending on the degree of activation by oxLDL. At low oxLDL levels LOX-1 activates the protective Oct-1/SIRT1 pathway, while at higher levels of the lipoprotein switches to the thrombogenic ERK1/2 pathway. These findings may be important for arterial thrombus formation in ACS and suggest that SIRT1 may represent a novel therapeutic target in this context.
Quality of life (QoL) in elderly patients (pts) with advanced NSCLC treated with nab-paclitaxel (nab-P) + carboplatin (C): Interim results from the ABOUND.70+ study
Authors: J. Weiss, E. Kim, K.I. Amiri, E. Anderson, S. Dakhil, D. Haggstrom, R. Jotte, K. Konduri, M. Modiano, T.J. Ong, A. Sanford, D. Smith, M. Socoteanu, J. Goldman, C. Langer
Journal: Annals of Oncology (2016)
NCOG-04. IMPAIRED FLUID COGNITION IN PATIENTS WITH GLIOMA OF THE FRONTAL AND PARIETAL LOBES
Authors: Stefan Lang, Ismael Gaxiola, Brad Goodyear, Paulo Federico, John Kelly
Journal: Neuro-Oncology (2016)

Patients with gliomas are known to have baseline cognitive impairment. However, the characteristics of these cognitive effects have not been well defined. Intellectual ability can be dichotomized into fluid and crystallized components. The objective of this pilot study was to assess the difference between measures of fluid and crystalized cognition in patients with frontal and parietal brain tumours. Seven healthy control subjects and ten patients with gliomas of the frontal or parietal lobes, completed all tests within the NIH Toolbox Cognitive Battery (NTCB). The NTCB consists of seven tasks: Dimensional Change Card Sort, Flanker Inhibitory Control and Attention, Picture Sequence Memory, Picture Vocabulary, Oral Reading Recognition, Pattern Comparison Processing Speed, and List Sorting Working Memory. From these tests, three composite scores are calculated. The Fluid cognition composite score is comprised of the Flanker, Dimensional Change Card Sort, Picture Sequence Memory, List Sorting, and Pattern Comparison tasks. The Crystallized Cognition Composite Score is comprised of the Picture Vocabulary Test and the Oral Reading Recognition Test. These tests are validated, normed, and corrected for age and education. Unpaired two sample t-test was used for statistical analysis. There was no statistically significant difference between the overall composite cognitive score in patients compared to controls (49.10 vs 57.29; p=0.21). However, compared to controls, patients demonstrate lower scores of fluid cognition (41.34 vs 57.57; p=0.036), whereas there was no difference in measures of crystalized cognition (57.34 vs 54.94; p=0.61). Within groups, patients had significantly lower scores of fluid cognition compared to crystalized cognition (p=0.021). Control subjects demonstrated no difference between these measures (p=0.55). Patients with gliomas of the frontal and parietal lobes demonstrate impaired fluid cognition with preserved crystallized cognition. This may be due to differential disruption in the underlying neural networks sub-serving these abilities.
Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC Alterations
Authors: Daniel J. Landsburg, Radhakrishnan Ramchandren, Amir Hafeez, Robert Gharavi, Tania Chander, Anna Ma, Micah M. Burch, Yasuhiro Oki
Journal: Blood (2016)
Impact of HLA Mismatch on the Incidence of Acute GVHD and Rejection after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation (RICT).
Authors: Takanori Teshima, K. Matsuo, K. Matsue, F. Kawano, S. Taniguchi, K. Hatanaka, S. Nakao, M. Tanimoto, M. Hara, T. Eto, A. Wake, Y. Abe, Y. Ohno, Y. Takemoto, M. Harada, S. Takahashi, Y. Ishida, Y. Kanda, M. Imamura, M. Kasai, Y. Takaue
Journal: Blood (2004)
Small cell lung carcinoma harbors targetable alterations including MYCL1 fusions responding to aurora kinase inhibitor
Authors: S. Ali, B. Kolla, M. Bailey, A.B. Schrock, S.J. Klempner, G.M. Frampton, D.A. Fabrizio, S.-H.I. Ou, J. He, J. Suh, J.S. Ross, P. Stephens, V. Miller, M. Patel
Journal: Annals of Oncology (2016)
Tumor infiltration by T lymphocytes correlates with the outcome of prostate cancer patients treated with salvage radiotherapy
Authors: V. Nardone, C. Botta, M.R. Ambrosio, T. Carfagno, P. Tini, M.T. Del Vecchio, M. Caraglia, P. Tagliaferri, L. Pirtoli, P. Correale
Journal: Annals of Oncology (2016)
Activation of Paired-Homeobox Gene PITX1 by Del(5)(q31) In T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Authors: Stefan Nagel, Letizia Venturini, Grzegorz K. Przybylski, Piotr Grabarczyk, Björn Schneider, Corinna Meyer, Maren Kaufmann, Christian A. Schmidt, Michaela Scherr, Hans G. Drexler, Roderick AF MacLeod
Journal: Blood (2010)
The Addition of sFLCR Improves ISS Prognostication in Multiple Myeloma (MM).
Authors: Marie-Christine Kyrtsonis, Theodoros P. Vassilakopoulos, Nikolitsa Kafasi, Dimitris Maltezas, Athanasios Anagnostopoulos, Evangelos Terpos, Evangelos Elefterakis-Papaiakovou, Anastasia Pouli, Panagiotis Repousis, Sossana Delimpasi, Konstantinos Anargyrou, Catherine Stefanoudaki, Eurydiki Michalis, Sotirios Sachanas, Tatiana Tzenou, Stavroula Masouridis, Maria Dimou, Maria K. Angelopoulou, Maria N. Dimopoulou, Marina P. Siakantaris, Evangelia M. Dimitriadou, Styliani I. Kokoris, Christina Kalpadakis, Panayiotis Panayiotidis, Meletios A. Dimopoulos, Gerassimos A. Pangalis
Journal: Blood (2007)